Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
Summary
Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. ET on Dec. 24, 2021. Get the full story at our sister site, Drug Delivery Business News.
Classifications
industries
No industries detected
applications
Web and Content Management
AskAI Classifications
Labels
Software Development
SaaS
Web Tools
Linked Companies
AddToAny
$10M to $25M